Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | LAVA-051: a novel bispecific T-cell engager for R/R hematological malignancies

Arnon Kater • 9 Jun 2022
EHA 2022
Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Leukemia Multiple Myeloma BiTEs LAVA-051

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses LAVA-051, a novel bispecific T-cell engager being investigated for the treatment of relapsed/refractory hematological malignancies. LAVA-051 engages gamma delta T-cells and has shown clinical effects in chronic lymphocytic leukemia (CLL) and multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Arnon Kater

2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023
1:46
Overcoming T-cell dysfunction
Arnon Kater • 6 Oct 2023
0:53
The future of CLL treatment
Arnon Kater • 6 Oct 2023
2:17
EPCORE CLL-1: epcoritamab in patients with R/R CLL & Richter's transformation
Arnon Kater • 6 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals